Literature DB >> 1323472

Immune-complex alveolitis in the rat: evidence for platelet activating factor and leukotrienes as mediators of the vascular lesions.

W T de Lima1, P Sirois, S Jancar.   

Abstract

In the present study we investigated the involvement of lipid mediators in an experimental model of immune-complex alveolitis induced in rat lungs by intrabronchial instillation of rabbit antibodies to ovalbumin followed by i.v. injection of the antigen. It was found that the reaction did not induce detectable oedema, as measured by the dry:wet weight ratio. A marked influx of neutrophils was observed in the bronchoalveolar lavage fluid, progressing from 6 to 24 h in parallel with the development of haemorrhagic lesions in lung parenchyma. The intensity of these lesions, evaluated by the concentration of extravascular haemoglobin, was not significantly affected by pretreatment of the animals with a cyclo-oxygenase inhibitor (indomethacin), a thromboxane inhibitor (econazole) or a thromboxane antagonist (L-655,240). However, the antagonists of platelet activating factor (PAF), WEB-2086 and BN-52021, and the lipoxygenase inhibitors, nor-dihydroguaiaretic acid and L-663,536, all significantly inhibited the haemorrhagic lesions. A peptide leukotriene antagonist (L-660,711) had no effect. Furthermore, the PAF antagonists inhibited the levels of LTB4, but not of PGE2 and thromboxane, released into the bronchoalveolar space 1 h after induction of the reaction. These results suggest that the haemorrhagic lesions in this model of immune-complex alveolitis are mediated by PAF and leukotrienes, possibly LTB4.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323472     DOI: 10.1016/0014-2999(92)90233-t

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Association of endothelin with lung hemorrhage induced by immune complexes in rats.

Authors:  C F P Teixeira; S Jancar; W T Lima; P D'Orléans-Juste; P Sirois
Journal:  Inflammation       Date:  2004-10       Impact factor: 4.092

2.  Beneficial effects of infrared light-emitting diode in corticosteroid-resistant asthma.

Authors:  Robson Alexandre Brochetti; Simone Klein; Paula Tatiane Alonso; Adriana Schapochnik; Amílcar Sabino Damazo; Michael R Hamblin; Maria Fernanda de Souza Setubal Destro; Adriana Lino-Dos-Santos-Franco
Journal:  Lasers Med Sci       Date:  2021-11-06       Impact factor: 3.161

3.  Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis.

Authors:  A A Steil; M C Garcia Rodriguez; A Alonso; M S Crespo; L Bosca
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

4.  Study of the effector mechanism involved in the production of haemorrhagic necrosis of the small intestine in rat passive anaphylaxis.

Authors:  M I Pellón; A A Steil; V Furió; M Sánchez Crespo
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

5.  Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice.

Authors:  Carolina Costola-de-Souza; Alison Ribeiro; Viviane Ferraz-de-Paula; Atilio Sersun Calefi; Thiago Pinheiro Arrais Aloia; João Antonio Gimenes-Júnior; Vinicius Izidio de Almeida; Milena Lobão Pinheiro; João Palermo-Neto
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

6.  Nitric oxide decreases intestinal haemorrhagic lesions in rat anaphylaxis independently of mast cell activation.

Authors:  J C Tavares; A Moreno; M S Crespo
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

7.  The putative role of ovary removal and progesterone when considering the effect of formaldehyde exposure on lung inflammation induced by ovalbumin.

Authors:  Adriana Lino-dos-Santos-Franco; Renata Midori Amemiya; Ana Paula Ligeiro de Oliveira; Amílcar Sabino Damazo; Ana Cristina Breithaupt-Faloppa; Luana Beatriz Vitoretti; Beatriz Golegã Acceturi; Wothan Tavares-de-Lima
Journal:  Clinics (Sao Paulo)       Date:  2013-12       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.